Explore more Johnson & Johnson sites:
Learn More About Janssen's Phase 3 COVID-19 Vaccine Candidate Clinical Trials
By clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
Learn More
By clicking this link, you’ll be leaving jnj.com and going to a third-party website not governed by the jnj.com privacy policy.
Share
Climate and Energy
Colbeck’s Corner wind farm in Carson County, Texas, provides more than 60% of Johnson & Johnson’s electricity use in the U.S.
s a healthcare company, Johnson & Johnson understands that climate health can affect human health. In fact, we’re seeing climate change impact health in new ways by changing infectious disease patterns and increasing the risk of drought and food insecurity. We have taken sustained, long-term action to reduce our greenhouse gas (GHG) emissions and we are encouraging our supply chain to do the same. We also support responsible climate and energy policy around the world.
Our Goals
As the world’s largest, most broadly based healthcare company, we know that human health and environmental healthy are inextricably linked. Healthy people need a healthy planet. Johnson & Johnson has a longstanding commitment to environmental health including two decades of public climate commitments. Building on our strong legacy of climate action, we are proud to announce Johnson & Johnson’s next generation of climate goals:
- By 2025, source 100% of our electricity needs from renewable sources
- By 2030, achieve carbon neutrality for our operations, going beyond our Science-Based Target to reduce absolute Scope 1 and 2 emissions 60% from 2016 levels
- By 2030, reduce absolute upstream Scope 3 emissions 20% from 2016 levels
Our Approach
For many years, we’ve participated in coalitions that publicly support actions to promote a low carbon economy and mitigate climate change, such as the World Wildlife Fund's Climate Savers Program, The Climate Group's RE100 program and the United Nations Framework Convention on Climate Change. We believe industry has an important role to play in responding to climate change by implementing voluntary reductions of GHGs within their control. As such, we have a long history of commitments and action to improve the energy efficiency of our facilities and source cleaner energy to power our operations.
Our Commitment to Energy Leadership
Highlights from Johnson & Johnson's 30 years of energy innovation and leadership.
1986
Established formal energy management program
2000
Established first enterprise-wide public commitment to reduce CO2 emissions based on Kyoto Protocol
2000
Developed internal CO2 capital relief program, which has resulted in 231 projects and 288,000 metric tons of CO2 saved per year over the past 15 years
2010
Announced goal to reduce CO2 emissions by 20% by 2020 adn increase on-site clean energy capacity to 50MW by 2015. Currently over 50 solar arrays and 4 wind turbines built, totaling 56MWs on our properties globally
2015
Supported UNFCCC Paris Climate agreement and committed to using 100% renewable electricity in our operations by joining RE100
2015
Executed long-term renewable electricity contracts increasing our global renewable electricity consumption to near 50%
2020
Launched 4th generation science-based climate commitments, accelerating our 100% renewable electricity commitment to 2025, committing to carbon neutrality in our operations and a 20% value chain emissions reduction by 2030
1986
2000
2000
2010
2015
2015
2020
We Are Taking Steps to Help Create Even Greater Impact
We are partnering with organizations like C40 Cities Climate Leadership Group—a network of the world's 90 megacities that are committed to climate leadership and action—to help fund programs that will link climate action with the benefits to air quality and human health.
We are a founding member of the Climate Leadership Council, a coalition of industry, NGO and thought leaders seeking to address climate issues through a carbon dividends framework.
Additional Resources
More From Johnson & Johnson
Johnson & Johnson just announced the launch of a Phase 3 clinical trial for its COVID-19 vaccine candidate. But what does this step in the process really mean? We asked two experts whose job it is to test vaccines to help demystify the clinical trial process—step by step.
The heart condition affects up to six million Americans, and raises the risk of stroke five-fold. One patient describes what it was like to learn she had atrial fibrillation—and the unexpected positive impact it has had on her life.
Njira Lugogo, M.D., is a pulmonologist at the University of Michigan who is leading a clinical study of an investigational COVID-19 vaccine candidate. She helps answer common questions people may have about the process, from what people over 60 need to know to how participants are being kept safe during the pandemic.
